dose-limiting side effects

dose-limiting side effects

drug effects that prevent a drug from being administered in higher doses.
Mentioned in ?
References in periodicals archive ?
The best results were obtained with acetaminophen and opioids, but there were dose-limiting side effects, and pain rebounded when the treatment was discontinued.
Currently available cholinesterase inhibitors "are nonselective and suffer from serious dose-limiting side effects," said Dr.
While we are encouraged with the efficacy we have seen to date, given that ICA-105665 has been well-tolerated by both healthy volunteers and patients up to the highest dose tested without dose-limiting side effects, we believe that it is prudent to investigate higher doses.
Healthcare providers also need to reassure patients that if dose-limiting side effects do occur and their dosages do need to be adjusted, the overall efficacy of their treatment will not be reduced.
An initial dose of 25 mg/day or 50 mg/day of sertraline was prescribed for patients aged 6-12 years and 13-18 years, respectively and was titrated upward to a maximum of 200 mg/day until satisfying clinical results were achieved without dose-limiting side effects.
Patients treated with aldoxorubicin in this clinical trial were delivered doxorubicin in a cumulative dose of more than 3u times the peak cumulative dose of standard doxorubicin with no observed cardiac toxicities, even though cardiac safety is considered one of the dose-limiting side effects for standard doxorubicin.
The company's strategic approach begins with the identification of drugs with dose-limiting side effects.
An initial dose of 25 mg/day or 50 mg/day of sertraline was prescribed for patients aged 6-12 years and 13-18 years, and was titrated upward to a maximum of 200 mg/day until satisfying clinical results were achieved without dose-limiting side effects.
Existing therapies for spasticity can have limited efficacy for some patients and may be associated with dose-limiting side effects.
Although 5-FU is a mainstay of contemporary cancer therapy, it has some therapeutic drawbacks, including that it must be given intravenously, it can cause severe and dose-limiting side effects, and it has variable blood and tissue levels which impact its anti-tumor activity and safety profile.
The most commonly prescribed therapies for spasticity are limited in efficacy and are associated with significant dose-limiting side effects including drowsiness, fatigue and cognitive impairment, resulting in high rates of therapy discontinuations.
No Dose-Limiting Side Effects in Phase 1b Clinical Trial at More Than a Four-Fold Increase in Standard Doxorubicin Dose -